Please login to the form below

Not currently logged in
Email:
Password:

Alapis opens veterinary companies in Serbia and Hungary

Alapis establishes two companies in Serbia and Hungary which will specialise in the production and trade of veterinary medicines and foods

Greek pharmaceutical and chemical company Alapis has established two companies, one in Serbia and another in Hungary, both of which will specialise in the production and trade of veterinary medicines and foods.

The Serbia-based operation is called Veterin Pharma Doo and has its headquarters in Beograd. The other company, based in Budapest, Hungary, is called Veterin Hungary. Alapis is the sole share holder in both companies.

Other purchasing activity
On 25 July, Alapis said that it had been selected as the highest bidder by the Serbian Privatisation Agency for the sale of a 68.3 per cent stake in pharmaceutical distribution company Sumadijalek after it bid EUR 2.2m.

Sumadijalek was founded in 1965 and had turnover of EUR 9.4m in FY05 with 48 per cent of its sales coming from pharmacies, clinics and public hospitals.

Alapis reported that negotiations would begin with the agency for the purpose of signing the contract of purchase.

In early July, Alapis revealed that it was in preliminary talks with Bayer Cropscience's local unit Bayer Hellas to acquire its pesticide plant in Viotia, Greece. As part of the transaction, Alapis said it expected to take over the production of crop chemicals in the region for Bayer.

Alapis already co-operates with Germany-headquartered Bayer on the production of veterinary drugs in Greece, Romania and Bulgaria.

1st August 2007

Share

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Evoke Kyne

Evoke Kyne is an award-winning communications agency that harnesses insight, experience and creativity to advance health and wellbeing around the world. We were founded on the belief that...

Latest intelligence

Main image2
Customers, content and change
By Dominic Tyer...
Report: Reinventing product and portfolio value for the biopharmaceutical industry
Gain practical advice on determining and communicating product and portfolio value, including why, in fast-paced and evolving markets, you need to consider the evidence requirements of a growing network of...
Neil Thompson
How AI is finally helping rare diseases gain more than just attention
By Neil Thompson...